<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59594">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330172</url>
  </required_header>
  <id_info>
    <org_study_id>B1312230009</org_study_id>
    <nct_id>NCT02330172</nct_id>
  </id_info>
  <brief_title>Sugammadex Provide Better Surgical Condition Compared With Neostigmine in Laryngeal Microsurgery.</brief_title>
  <official_title>Comparison Sugammadex With Neostigmine in Laryngeal Microsurgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to make a comparison of surgical condition and recovery time between
      rocuronium 0.45 mg/kg and neostigmine group and rocuronium 0.9 mg/kg and sugammadex group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to make a comparison of surgical condition and recovery time between
      moderate neuromuscular bloackade with reversal using neostigmine group and deep
      neuromuscular bloackade with reversal using sugammadex group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>satisfaction score of surgical condition</measure>
    <time_frame>intraoperative surgical consition</time_frame>
    <description>satisfaction score of surgical condition using 7 point liker's scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recovery time from neuromuscular blockade</measure>
    <time_frame>from the injection of neostigmine or sugammadex up to 30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>rocuronium 0.45 - neostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>when anesthetic induction, inrocuronium 0.45 mg/kg will be administered for muscle relaxation.
When the end of operation, a injection of neostigmine or sugammadex will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rocuronium 0.9 - sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>When anesthetic induction, rocuronium 0.9 mg/kg will be injected to rocuronium 0.9 - sugammadex group for muscle relaxation.
When the end of operation,, a injection of neostigmine or sugammadex be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Injection of neostigmine or sugammadex</intervention_name>
    <description>At anesthetic induction, rocuronium 0.45 to rocuronium 0.45 - neostigmine group or rocuronium 0.9 mg/kg to rocuronium 0.9 - sugammadex group will be injected for muscle relaxation.
During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. After operation, neostigmine 50 mcg/kg or sugammadex 4 mg/kgl be injected.</description>
    <arm_group_label>rocuronium 0.45 - neostigmine</arm_group_label>
    <arm_group_label>rocuronium 0.9 - sugammadex</arm_group_label>
    <other_name>neostigmin or sugammadex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologist Physical status classification 1 or 2 elective
             laryngeal microsurgery under general anesthesia

        Exclusion Criteria:

          -  BMI &gt;25 or &lt; 20 kg/m2 Patients taking intercurrent medication Glutamic Oxalacetate
             Transaminase or Glutamic Pyruvate Transaminase &gt; 40 IU/L, Cr &gt; 1.4 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ah Young Oh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bungdang Seoul National University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eunsu Choi</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>September 6, 2016</lastchanged_date>
  <firstreceived_date>December 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
